Last reviewed · How we verify
VACCINE: 13-valent pneumococcal conjugate vaccine
VACCINE: 13-valent pneumococcal conjugate vaccine is a Biologic drug developed by Pfizer. It is currently FDA-approved. Also known as: 13vPnC.
The 13-valent pneumococcal conjugate vaccine, marketed by Pfizer, holds a significant position in the pneumococcal vaccine market. A key strength is the protection it offers against 13 serotypes of Streptococcus pneumoniae, which has solidified its market presence. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | VACCINE: 13-valent pneumococcal conjugate vaccine |
|---|---|
| Also known as | 13vPnC |
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks) (PHASE3)
- A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults (PHASE1)
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (PHASE1, PHASE2)
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (PHASE3)
- Vaccine Responses in Patients With B Cell Malignancies (PHASE4)
- Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (PHASE2)
- A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VACCINE: 13-valent pneumococcal conjugate vaccine CI brief — competitive landscape report
- VACCINE: 13-valent pneumococcal conjugate vaccine updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about VACCINE: 13-valent pneumococcal conjugate vaccine
What is VACCINE: 13-valent pneumococcal conjugate vaccine?
Who makes VACCINE: 13-valent pneumococcal conjugate vaccine?
Is VACCINE: 13-valent pneumococcal conjugate vaccine also known as anything else?
What development phase is VACCINE: 13-valent pneumococcal conjugate vaccine in?
Related
- Manufacturer: Pfizer — full pipeline
- Also known as: 13vPnC
- Compare: VACCINE: 13-valent pneumococcal conjugate vaccine vs similar drugs
- Pricing: VACCINE: 13-valent pneumococcal conjugate vaccine cost, discount & access